News & Updates

Individuals with acute COVID-19 who receive prompt antiviral treatment, such as ensitrelvir, nirmatrelvir, or molnupiravir, in the outpatient setting may be less likely to experience post–COVID-19 condition (PCC) compared with those who receive no treatment.

A University of Hong Kong analysis shows one-off hepatitis C virus (HCV) screening of persons in custody (PICs) to be cost-effective and reduce the rates of HCV-related compensated and decompensated cirrhosis (DC), hepatocellular carcinoma (HCC), and HCV-related mortality.

People living with HIV-1 (PLWH) who discontinued traditional non-nucleoside reverse transcriptase inhibitor (NNRTI)- and boosted integrase strand transfer inhibitor (INSTI)-based regimens have maintained viral suppression following their switch to the next-generation NNRTI ainuovirine coformulated with lamivudine and tenofovir DF (ANV/3TC/TDF), as shown by the 144-week open-label results from the SPRINT* post-study presented at ESCMID Global 2026.

A payer-perspective study from the University of Hong Kong (HKU) indicates that single-dose baloxavir is a more cost-effective outpatient treatment option for seasonal influenza than oseltamivir, despite baloxavir’s higher acquisition cost.

Treatment with colchicine and famotidine plus loratadine, in addition to specialist supportive care, can substantially ease severe fatigue among patients suffering from long COVID, as shown by the results of the STIMULATE ICP trial.